Thyroid carcinoma, version 2.2014 Journal Article


Authors: Tuttle, R. M.; Haddad, R. I.; Ball, D. W.; Byrd, D.; Dickson, P.; Duh, Q. Y.; Ehya, H.; Haymart, M.; Hoh, C.; Hunt, J. P.; Iagaru, A.; Kandeel, F.; Kopp, P.; Lamonica, D. M.; Lydiatt, W. M.; McCaffrey, J.; Moley, J. F.; Parks, L.; Raeburn, C. D.; Ridge, J. A.; Ringel, M. D.; Scheri, R. P.; Shah, J. P.; Sherman, S. I.; Sturgeon, C.; Waguespack, S. G.; Wang, T. N.; Wirth, L. J.; Hoffmann, K. G.; Hughes, M.
Article Title: Thyroid carcinoma, version 2.2014
Abstract: These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 12
Issue: 12
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2014-12-01
Start Page: 1671
End Page: 1680
Language: English
PROVIDER: scopus
PUBMED: 25505208
DOI/URL:
Notes: Export Date: 2 January 2015 -- Source: Scopus
Citation Impact
MSK Authors
  1. Robert M Tuttle
    417 Tuttle
  2. Jatin P Shah
    646 Shah
Related MSK Work